ГРЭБЕР Михаэль (US),ЛЕОНИ Мэтью Джеймс (US),ВАГНЕР Натали (FR)
申请号：
RU2013113184/15
公开号：
RU2013113184A
申请日:
2011.09.27
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating rosacea-related erythema in a patient in need of such treatment, the method comprising the step of topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or its pharmaceutically acceptable salt to the erythema focus on the patient’s skin. 2. The method according to claim 1, wherein the pharmaceutically acceptable salt of brimonidine is brimonidine tartrate. The method of claim 1, wherein the pharmaceutically acceptable salt of oxymetazoline is oxymetazoline hydrochloride. The method according to claim 1, wherein the brimonidine or a pharmaceutically acceptable salt thereof is present in a minimum amount of about 0.01% and a maximum amount of about 5% with respect to the total weight of the composition. The method according to claim 1, wherein oxymetazoline or a pharmaceutically acceptable salt thereof is present in a minimum amount of about 0.01% and a maximum amount of about 5% with respect to the total weight of the composition. The method of claim 1, wherein the active ingredients are only brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof. A method for treating rosacea-related telangiectasia in a patient in need of such treatment, the method comprising the step of topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the focal point of telangiectasia on the patient's skin. The method of claim 7, wherein the pharmaceutically acceptable salt of brimonidine is brimonidine tartrate. The method of claim 7, wherein the pharmaceutically1. Способ лечения эритемы, связанной с розацеа, у пациента, нуждающегося в таком лечении, причем способ содержит этап, на котором топикально вводят эффективное количество комбинации бримонидина или его фармацевтически приемлемой
